Drug Profile
Research programme: colistin potentiators - Synereca Pharmaceuticals
Latest Information Update: 02 May 2023
Price :
$50
*
At a glance
- Originator Synereca Pharmaceuticals
- Class Polymixins; Small molecules
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acinetobacter infections
Most Recent Events
- 02 May 2023 Discontinued - Preclinical for Acinetobacter infections in USA (PO)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Acinetobacter-infections in USA (PO)
- 17 Sep 2014 Preclinical trials in Acinetobacter infections in USA (PO)